# Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Canonical URL: https://biopharmsignal.com/news/AMRX/amneal-to-participate-in-goldman-sachs-47th-annual-global-healthcare-conference-2026
Ticker: AMRX
Company: Amneal Pharmaceuticals
Source: Amneal Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.amneal.com
## Summary

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will participate and present at Goldman Sachs 47 th Annual Global Healthcare Conference 2026 being held on June 8-10 at the Loews Miami Beach Hotel in Miami, FL. A company presentation will take place on Tuesday June 9, 2026, at 8:40AM EDT. A live webcast of the presentation will be available here . About

## Article Body
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will participate and present at Goldman Sachs 47 th Annual Global Healthcare Conference 2026 being held on June 8-10.

A company presentation will take place on Tuesday June 9, 2026, at 8:40AM EDT. A live webcast of the presentation will be available here .

About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Investor Contact Anthony DiMeo VP, Investor Relations anthony.dimeo@amneal.com

Media Contact Brandon Skop Sr. Director, Corporate Communications brandon.skop@amneal.com

Source: Amneal Pharmaceuticals LLC
## Recent Company News
- 2026-07-17 12:00 EST — [Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations](https://biopharmsignal.com/news/AMRX/amneal-expands-iohexol-injection-portfolio-with-u-s-fda-approval-of-additional-s-5f3ad56b) — Source: Amneal Pharmaceuticals
- 2026-07-09 20:05 EST — [Amneal to Report Second Quarter 2026 Results on July 30, 2026](https://biopharmsignal.com/news/AMRX/amneal-to-report-second-quarter-2026-results-on-july-30-2026-e7677e7f) — Source: Amneal Pharmaceuticals
- 2026-07-08 20:30 EST — [Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector](https://biopharmsignal.com/news/AMRX/amneal-and-adalvo-announce-fda-acceptance-for-review-of-two-u-s-andas-for-generi-0a6b37df) — Source: Amneal Pharmaceuticals
- 2026-07-01 12:30 EST — [Amneal’s New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program](https://biopharmsignal.com/news/AMRX/amneal-s-new-u-s-sterile-manufacturing-facility-selected-for-fda-precheck-pilot--2719d102) — Source: Amneal Pharmaceuticals
- 2026-06-29 07:00 EST — [Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations](https://biopharmsignal.com/news/AMRX/zambon-and-amneal-announce-positive-chmp-opinion-for-hopledo-ipx203-for-adults-w-6b0e1405) — Source: Amneal Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)